Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2016

Pharma News, 2016

Breast milk protein could be used in fight against antibiotic resistance

Breast milk protein could be used in fight against antibiotic resistance

An antibiotic developed from human breast milk could combat certain drug-resistant bacteria, British scientists have found.

Biotech Can-Fite step closer to securing US patent for Viagra drug for diabetics

Biotech Can-Fite step closer to securing US patent for Viagra drug for diabetics

Israeli biotech company Can-Fite BioPharma Ltd is a step closer to securing US patent for its drug CF602, touted as a Viagra alternative for diabetics.

To Fight ‘Superbugs,’ Drug Makers Call for Incentives to Develop Antibiotics

To Fight ‘Superbugs,’ Drug Makers Call for Incentives to Develop Antibiotics

More than 80 pharmaceutical and diagnostic companies from around the world are calling for new economic models to spur development of badly needed new antibiotics and to fight the rising global threat...

Scientists use protein-blocker to stop the spread of leukaemia

Scientists use protein-blocker to stop the spread of leukaemia

Acute myeloid leukaemia (AML) is one of the most aggressive and damaging types of cancer there is.

Are beards GOOD for your health? Yes! Huge variety of bacteria found in facial hair 'could help develop new antibiotics'

Are beards GOOD for your health? Yes! Huge variety of bacteria found in facial hair 'could help develop new antibiotics'

Tests on the beards of random men found more than 100 types of bacteria.

Allergan’s trial drug for IBS-D shows positive results in late stage trials

Allergan’s trial drug for IBS-D shows positive results in late stage trials

Allergan (NYSE.

GlaxoSmithKline scientists accused of stealing drug R&D secrets for China scheme

GlaxoSmithKline scientists accused of stealing drug R&D secrets for China scheme

Yu Xue had a hard-earned reputation as a top chemist while she was working for GlaxoSmithKline ($GSK) in its Upper Merion, PA, facility.

NIH announces $240 million project to map human genomes

NIH announces $240 million project to map human genomes

The federal government is funding a monumental project to map 200,000 human genomes in an effort to understand the genetic causes of common diseases such as cardiovascular disease, diabetes, epilepsy ...

AbbVie and Roche's cancer drug snags another 'breakthrough' tag

AbbVie and Roche's cancer drug snags another 'breakthrough' tag

AbbVie ($ABBV) and Roche's ($RHHBY) cancer drug venetoclax, awaiting FDA approval, picked up another breakthrough therapy nod from the agency for its potential as part of a combina...

PD-L1 inhibition well-tolerated, active in metastatic RCC

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 (PD-L1) inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinom...

Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis

Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis

INDIANAPOLIS, Jan.

FDA grants priority review status to Eisai’s sNDA for anticancer drug lenvatinib

FDA grants priority review status to Eisai’s sNDA for anticancer drug lenvatinib

The US Food and Drug Administration (FDA) has granted priority review status to the supplemental new drug application (sNDA) submitted by Eisai for its anticancer agent lenvatinib mesy...

52 53 54 555657 58